#USA #Nashville #Cancer Treatment #Tennessee Oncology #Casey Chollet-Lipscomb

Tennessee Oncology Welcomes Dr. Casey Chollet-Lipscomb as Chief Medical Officer

Tennessee Oncology, a prominent independent oncology practice in the United States, has officially announced the appointment of Dr. Casey Chollet-Lipscomb as its new Chief Medical Officer. This transition marks a significant step in the organization’s dedication to advancing cancer care, showcasing a commitment to leadership and innovation within the oncology field.

Dr. Chollet-Lipscomb’s Journey

Dr. Chollet-Lipscomb, who joined Tennessee Oncology in 2014, has played a vital role in the organization’s progress. Prior to her new position, she served as Executive Vice President of Physician Services and had previously led the Radiation Oncology Division. Her extensive experience and contributions have also included sitting on Tennessee Oncology’s Board of Directors since 2018, where she has helped guide the organization’s strategic vision.

Dr. Chollet-Lipscomb’s tenure has been characterized by her focus on enhancing clinical quality, support for physicians, and advocacy for health policy. Her leadership has fostered deeper community partnerships and initiated several crucial programs that aim to elevate patient care and services offered by Tennessee Oncology.

Vision and Leadership

In her new role as Chief Medical Officer, Dr. Chollet-Lipscomb aims to further Tennessee Oncology's mission of delivering high-quality, compassionate cancer care. Her appointment is not only a recognition of her previous achievements but also a reflection of the organization's belief in her potential to lead further innovations and improvements in patient care.

Natalie Dickson, the current CEO and President of Tennessee Oncology, expressed her enthusiasm regarding Dr. Chollet-Lipscomb’s appointment. She stated, “This appointment is a well-earned recognition of her exceptional leadership, unwavering dedication, and lasting impact on both our practice and the community we serve.” Such acknowledgment underscores the organization's trust in her vision and capability to drive success.

Continuing Impact in Oncology

Dr. Chollet-Lipscomb's influence extends beyond Tennessee Oncology. She is actively involved at the national level, serving on the Board of Directors for the American Society for Radiation Oncology (ASTRO). Her work influences cancer care policy on both federal and state fronts, showcasing her dedication to improving oncology practices nationwide.

Within Tennessee Oncology, Dr. Chollet-Lipscomb will collaborate closely with other executive team members, including Johnetta Blakely, MD, who will remain as Executive Vice President of Quality and Clinic Operations, and Ted Arrowsmith, MD, who maintains his role as Executive Vice President of Therapeutics. Together with Dr. Chollet-Lipscomb, they form a leadership team that is well-equipped to address the evolving challenges of cancer treatment.

Commitment to Patient Care

Dr. Chollet-Lipscomb holds a medical degree from the University of Tennessee, further complemented by a residency at Loyola University Medical Center in Chicago and experience as an attending physician at Duke University. These credentials are a testament to her expertise and capability to lead the organization effectively.

The foundation of Tennessee Oncology was laid in 1976, with a mission aimed at providing accessible high-quality cancer care and leveraging clinical research for patients in their communities. By appointing leaders like Dr. Chollet-Lipscomb, the organization continues to pursue this mission fervently, ensuring that the nearly half of Tennessee’s cancer patients treated across its 36 clinics receive the best possible care.

For more information about Tennessee Oncology and its commitment to providing outstanding cancer treatment, visit www.tnoncology.com.

Conclusion

The appointment of Dr. Casey Chollet-Lipscomb as Chief Medical Officer marks a pivotal moment for Tennessee Oncology. Her established track record and dedication to enhancing cancer care signal a promising future, ensuring that cancer patients in Tennessee continue to receive compassionate and cutting-edge treatment.